Important factors include family history, which still remains an important additional clinical consideration for families that carry pathogenic variants in PALB2 [28] and the role of the polygenic risk score that has, similar to BRCA1 and BRCA2 pathogenic variant carriers, recently been demonstrated to modify the risk of breast cancer for CHEK2 pathogenic variant carriers [34]. This evidence concerns the gene BRCA2 and breast carcinoma.